EXPRESSION OF MUTANT P53, C-ERBB-2 AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN TRANSITIONAL CELL-CARCINOMA OF THE HUMAN URINARY-BLADDER

被引:186
作者
WRIGHT, C
MELLON, K
JOHNSTON, P
LANE, DP
HARRIS, AL
HORNE, CHW
NEAL, DE
机构
[1] UNIV NEWCASTLE UPON TYNE,DEPT PATHOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
[2] UNIV NEWCASTLE UPON TYNE,DEPT SURG UROL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
[3] JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND
[4] IMPERIAL CANC RES FUND,MOLEC IMMUNOCHEM LAB,POTTERS BAR,HERTS,ENGLAND
关键词
D O I
10.1038/bjc.1991.211
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2 proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical association was found between p53 and EGFr expression. Weakly positive associations were found between the expression of c-erbB-2 and p53 and between muscle invasive tumours and increased expression of c-erbB-2. Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing prognosis.
引用
收藏
页码:967 / 970
页数:4
相关论文
共 41 条
[1]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[2]   BREAST-CANCER AND A PROTO-ONCOGENE [J].
BARNES, DM .
BRITISH MEDICAL JOURNAL, 1989, 299 (6707) :1061-1062
[3]  
BARTEK J, 1990, ONCOGENE, V5, P893
[4]   MOUSE P53 INHIBITS SV40 ORIGIN-DEPENDENT DNA-REPLICATION [J].
BRAITHWAITE, AW ;
STURZBECHER, HW ;
ADDISON, C ;
PALMER, C ;
RUDGE, K ;
JENKINS, JR .
NATURE, 1987, 329 (6138) :458-460
[5]   P53 EXPRESSION IN BREAST-CANCER [J].
CATTORETTI, G ;
RILKE, F ;
ANDREOLA, S ;
DAMATO, L ;
DELIA, D .
INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (02) :178-183
[6]   NCL-CB11, A NEW MONOCLONAL-ANTIBODY RECOGNIZING THE INTERNAL DOMAIN OF THE C-ERBB-2 ONCOGENE PROTEIN EFFECTIVE FOR USE ON FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE [J].
CORBETT, IP ;
HENRY, JA ;
ANGUS, B ;
WATCHORN, CJ ;
WILKINSON, L ;
HENNESSY, C ;
GULLICK, WJ ;
TUZI, NL ;
MAY, FEB ;
WESTLEY, BR ;
HORNE, CHW .
JOURNAL OF PATHOLOGY, 1990, 161 (01) :15-25
[7]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093
[8]   P53 AND DNA POLYMERASE-ALPHA COMPETE FOR BINDING TO SV40 T-ANTIGEN [J].
GANNON, JV ;
LANE, DP .
NATURE, 1987, 329 (6138) :456-458
[9]   ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM [J].
GANNON, JV ;
GREAVES, R ;
IGGO, R ;
LANE, DP .
EMBO JOURNAL, 1990, 9 (05) :1595-1602
[10]  
GUSTERSON BA, 1988, MOL CELL PROBE, V2, P383